New immune cell therapy targets MS in first human safety trial
NCT ID NCT07523100
First seen Apr 14, 2026 · Last updated May 20, 2026 · Updated 7 times
Summary
This early-stage study tests whether a new immune cell treatment called universal STAR-T cells is safe for people with multiple sclerosis (MS). About 24 adults with progressive or relapsing-remitting MS who have no other treatment options will receive the cells in increasing doses. The main goal is to check for side effects, while also looking at whether the therapy can slow disease worsening over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, 430030, China
Conditions
Explore the condition pages connected to this study.